2020

Documents to upload   in French: Résultats des votes de l’assemblée générale mixte du 28 mai 2020 – Résolutions ordinaires in French: Résultats des votes de l’assemblée générale mixte du 28 mai 2020 – Résolutions extraordinaires in French: Avis de convocation / avis de réunion In French: Lettre aux actionnaires et procédure de vote VOTACCESS…

Details

Biophytis Annual General Meeting

Biophytis Annual General Meeting We are pleased to invite you to the Biophytis Combined General Meeting which will be held following a second call in closed session on May 10 at 5:00 pm CET. The Combined General Meeting will be broadcast live (audio webcast) in two sessions: At 5pm CET in French, At 6pm CETin…

Details

COVID-19: COVA clinical program

  SEVERE ACUTE RESPIRATORY INFECTIONS: COVA CLINICAL PROGRAMME   1. Respiratory infections such as Covid-19 cause many hospital admissions and deaths According to the World Health Organisation (WHO), viral respiratory infections kill thousands of patients worldwide every year. In 2023, more than 230,000 patients died from COVID-19, out of a total of almost 7 million…

Details
Notre science Biophytis

2020

Posters & Publications 2020 SARA program: the use of BIO101, a MAS receptor agonist, for the treatment of sarcopenia. Industry sponsored session, annual digital meeting of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD). Tourette et al. SARA program: Preliminary Findings & Implications from SARA-OBS Study and Its Impact on SARA-INT Study. Dioh et al.…

Details

SEC Filings

SEC Filings Filing Date Form Description January 14, 2025 6-K On January 14, 2025, Biophytis S.A. issued a press release announcing that the company enters exclusive negotiations with a Chinese pharmaceutical company to license BIO101. January 6, 2025 6-K On January 6, 2025, Biophytis S.A. (the “Company”) issued a press release announcing the temporary suspension…

Details

AMF Regulated Information

Regulated Information In French: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 janvier 2025 In French: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2024 In French: Information mensuelle relative au nombre total des…

Details
Notre science Biophytis

2014

Posters & Publications 2014 The SARCOB program: a french consortium for developing drug candidate and nutraceutical targeting sarcopenic obesity. Dioh et al. Poster presentation at the 5th International Conference on Frailty & Sarcopenia Research (ICFSR), March 12-14, 2014, Barcelona, Spain. Abstract published in The Journal of Frailty & Aging, 3(1), 72-73, Abstract P186.

Details
Notre science Biophytis

2015

Posters & Publications 2015 BIO101, a drug candidate targeting sarcopenic obesity through MAS receptor activation. Raynal et al. Poster presentation at the 8th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 4-6, 2015, Paris, France. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 6(4), 429. Abstract 1-76.

Details